AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Astrazeneca (AZN) closed the most recent trading day at $69.45, moving +1.97% from the previous trading session.

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1 This additional indication for FASENRA was supported by evidence from TATE, an open-label, multinational, no.

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

AstraZeneca PLC (LSE:AZN) has increased its annual dividend by 7%, bringing it up to $3.10 (£2.5) per share. It marks the highest annual dividend increase in recent years, having only shifted from $2.8 to $2.9 between 2019 and 2023.

AstraZeneca offers 7% dividend sweetener on day of crucial pay vote

AstraZeneca said on Thursday it intends to increase annual dividend for 2024 by 7% to $3.10 per share, betting on strong performance and cash generation on the back of its blockbuster drugs and several recent acquisitions.

AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM

Tomorrow's shareholder vote on AstraZeneca PLC (LSE:AZN) boss Pascal Soriot's compensation represents a microcosm of the broader debate around executive entitlement and the disparity in corporate values on both sides of the Atlantic. Some argue that Soriot's exorbitant pay package is an egregious affront to moral decency, while others, including some of AstraZeneca's own shareholders, point to the US as proof that he's actually underpaid.

AstraZeneca pay debate exposes disparity in US-UK corporate values

Eli Lilly

STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, today announced that Professor Jan Lundberg invests in the company and is proposed as a new member of the company's board of directors. Professor Jan Lundberg has more than 25 years of experience from leading positions in global pharmaceutical companies, including as global head of research at Astra and then AstraZeneca (1996 - 2009) and global head of research and development at Eli Lilly (2010 - 2018).

Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board

ASML Hld

Diageo

Hermes International

HSBC Holdings

L'Oreal SA

LVMH Moet Hennessy Louis Vuitton

Nestle SA

Novo Nordisk

Novartis

Prosus NV

Roche Holding AG

SAP SE

Siemens AG

Sanofi

TotalEnergies SE

Unilever

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.

FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors.

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this ind.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

Daiichi Sankyo Co Ltd

The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.

US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors

AstraZeneca's (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase III ADRIATIC study.

AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study

AstraZeneca positive data from Imfinzi's Phase III ADRIATIC trial follows the raft of positive readouts and approvals across a range of cancer types, notes Shore Capital. Already these have stimulated a strong uptick in sales momentum for its burgeoning IO (immunotherapy) franchise during 2023 ($4.24bn, +55% CER).

AstraZeneca cancer trial readout underlines immuno opportunity, suggests broker

AstraZeneca has reported that Imfinzi significantly improved survival rates in the latest trial of the immunotherapy-based blockbuster cancer drug. Results from the Phase III ADRIATIC study in people suffering limited-stage small cell lung cancer (SCLC) treated with Imfinzi showed a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS)and progression-free survival (PFS), said the pharma giant.

AstraZeneca reports 'significant' patient improvement in latest Imfinzi cancer trial

Drugmaker AstraZeneca said on Friday its blockbuster cancer drug Imfinzi showed "significant and clinically meaningful" improvement in the primary goals of a late-stage trial designed for an aggressive type of lung cancer.

AstraZeneca's Imfinzi shows promise in treating aggressive lung cancer

Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.

Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion

AstraZeneca PLC (LSE:AZN) led the fallers on the main index, down 1.3% and echoing falls seen among US peers overnight.  It follows surprise news that federal payment rates to Medicare insurers next year will be lower than analysts predicted, The Centers for Medicare and Medicaid Services said that 2025 payment rates will be in line with a proposal at the start of the year that the insurance industry had argued was too low.

AstraZeneca leads fallers echoing Wall Street's Medicaid surprise

AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.

AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. The Prescription Drug User Fee Act date, the US Food and Drug Administration (FDA) action.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. Datopotamab deruxtecan is a specifically e.

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Astrazeneca (AZN) concluded the recent trading session at $67.25, signifying a -0.74% move from its prior day's close.

Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significan.

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

Ford Motor Company

Barrick Gold

Lockheed Martin

Rio Tinto plc Sponsored

AT&T

Vale S.A.

Blue-chip stocks are associated with a low-beta, stable returns, and passive dividend income for investors. However, not all blue-chip stocks are comparable when it comes to returns over a time-frame.

7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years

News for AstraZeneca Stock (AZN)